Infectious Disease Care
Carbavance® (meropenem-vaborbactam), an investigational agent, is a combination of the carbapenem, meropenem, and the novel beta-lactamase inhibitor vaborbactam (formerly known as RPX7009). Meropenem-vaborbactam is being developed to treat serious gram-negative infections, such as cUTIs.
For information on ongoing clinical trials click here.
The above investigational agent is not approved for commercial use in any market; the safety and efficacy has not been evaluated by any regulatory authority for the uses described.
Global Medical Information
The Global Health Science Center (GHSC) Medical Professionals are available to answer your medical information requests, or receive adverse event reports, other safety related information, and product complaints.
Please click below to contact the Global Health Science Center.
Alternatively, adverse events may be reported to the FDA MedWatch Reporting System by phone at 1 800 FDA 1088 (1 800 332 1088) or by mail using Form FDA 3500 at www.fda.gov/medwatch